Gene expression tests provide better estimates of cancer aggressiveness and aid decision-making in treating men with prostate cancer. In a new study from the Yale Cancer Center, researchers found significant regional differences in the use of genomic tests for prostate cancer and asked questions about access and other factors that could fuel the rapid adoption of new cancer technologies. The study is published online today in the journal JAMA Oncology.
Little was known about how genome testing was used in routine clinical care. We wanted to understand the national absorption patterns in regions in the United States. One of the interesting things we uncovered was the extent of regional differences in the use of genomic tests. «
Michael Leapman, MD, assistant professor of urology, clinical program director of the Prostate and Urologic Cancer Program at Smilow Cancer Hospital and Yale Cancer Center, and lead author of the study
The study examined data from 92. 418 patients, ages 40 to 89, diagnosed with prostate cancer between 2012 and 2018, using insurance claims from Blue Cross Blue Shield Axis®, the largest source of data on health insurance claims, providers and costs. Researchers looked for trends in the use of tests and used some form of statistical modeling to uncover groups of regions that had similar uptake patterns. The results showed that the adoption of commercial tissue-based genomic testing for prostate cancer varied widely across the US at the regional level. S.. . and may be associated with contextual actions related to socio-economic status and patterns of prostate cancer treatment.
« In some regions, little or no genomic testing was performed while in other regions few applications were used, which means the decisions to be tested are very discretionary, » Leapman said. « In addition, there were groups of geographically unrelated regions that grew at a similar rate over time. These findings raise questions about common factors that could fuel the rapid adoption of new cancer technologies. «
Study scientists added that more research is needed to clarify the contribution of patient-level factors to testing, as well as the effectiveness of these tests in improving clinical decision-making.
Tags: cancer, cancer prevention, cancer treatment, copper, gene, genome, healthcare, hospital, medicine, mortality, oncology, prostate, prostate cancer, research, urology
News-Medical spoke to researchers about their latest research on beta blockers and how they could potentially be used to treat COVID-19.
Dr. . Albert Rizzo speaks to News-Medical about the importance of wearing masks to control the spread of COVID-19.
In this interview, News-Medical speaks to Dr. . Jan Westerink on recent studies of Novo Nordisk’s semaglutide and its potential benefits for type 2 diabetes patients that he and Novo Nordisk worked on.
News-Medical. Net offers this medical information service in accordance
with these terms and conditions.
Please note that medical information has been found
on this website is intended to support, not replace, the relationship
between patient and doctor / physician and the medical advice they can give.
Prostate Cancer, Research, Urology, Regional Variation, Genetic Testing
LevelMagazine – AU – Researchers note significant regional differences in the use of genome tests for prostate cancer
Related Title :
– Researchers Find Significant Regional Differences firm in using genome tests for prostate cancer